Rocket Pharmaceuticals (RCKT) Preferred Stock Liabilities (2014 - 2015)

Rocket Pharmaceuticals (RCKT) reported Preferred Stock Liabilities of $46.4 million for Q3 2015, up 8364.05% sequentially from $548000.0 in Q2 2015.

Rocket Pharmaceuticals (RCKT) Preferred Stock Liabilities (2014 - 2015) Analysis & Trends

Rocket Pharmaceuticals (RCKT) has 2 years of Preferred Stock Liabilities data on file, last reported at $46.4 million in Q3 2015.

For the quarter ending Q3 2015, Preferred Stock Liabilities changed N/A year-over-year to $46.4 million; the trailing twelve-month figure through Sep 2015 stood at $46.4 million (changed N/A YoY), and the FY2014 full-year result was $46.8 million, changed N/A from the prior year.
Preferred Stock Liabilities grew to $46.4 million in Q3 2015, from $548000.0 in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $46.8 million in Q4 2014 to a low of $548000.0 in Q2 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Rocket Pharmaceuticals	357.93 Mn	357.93 Mn	-	-

Download Data